INCHEON, South Korea and CAMBRIDGE, MA, USA I September 20, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...
OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...
OPUVIZ has been recommended for approval in adult patients for the treatment of neovascular age related macular degeneration, visual impairment due to macular oedema secondary to retinal vein ...
Retinal Vein Occlusion (RVO) occurs when the vein draining blood from the retina is blocked, leading to complications such as macular edema and vision loss.